里腐霉,一种在哺乳动物中具有致病潜力的水生卵菌,导致狗的胃肠道和皮肤疾病。Mefenoxam,一种农业抗霉菌化合物,在一些病例报告中,已证明具有体外抑制阴间假单胞菌生长的能力,并且与治疗胃肠道化脓症的功效有关。搜索了2013年至2020年在佛罗里达大学小动物医院就诊并接受美芬沙姆治疗的狗的电子病历。在先前明确诊断后,将狗纳入本研究,并使用培养物进行任何一种生物鉴定,PCR,或抗体ELISA,或这些测试的组合,有或没有支持性组织病理学分析。自2013年以来,美芬沙姆已对25只皮肤化脓症犬和16只胃肠道化脓症犬进行了给药。在胃肠道和皮肤化脓组中,美芬西坦的给药与大约51%的存活率相关.皮肤组(245天(52-530))和胃肠道组(90天(21-203))之间的死亡时间存在统计学上的显着差异;感染皮肤化脓症的狗在诊断出患有该疾病后存活时间明显更长(p=0.035)。这项研究中的狗经历了存活率和死亡时间的增加,在没有美芬沙姆副作用的情况下,与以前发表的文献相比。这项回顾性研究的结果,有一些限制,是有希望的,并应促使进一步研究使用美芬沙姆治疗胃肠道和皮肤化脓症。
Pythium insidiosum, an aquatic oomycete with pathogenic potential in mammals, causes gastrointestinal and cutaneous disease in dogs. Mefenoxam, an agricultural anti-oomycotic compound, has a demonstrated the ability to inhibit P. insidiosum growth in vitro and has been associated with efficacy in treating gastrointestinal pythiosis in several case reports. Electronic medical records of dogs seen at University of Florida Small Animal Hospital and treated with mefenoxam between 2013 and 2020 were searched. Dogs were included in this
study upon previous definitive diagnosis with either organism identification using culture, PCR, or antibody ELISA, or a combination of these tests with or without supportive histopathological analysis. Since 2013, mefenoxam had been administered to 25 dogs with cutaneous pythiosis and 16 dogs with gastrointestinal
pythiosis. In both gastrointestinal and cutaneous
pythiosis groups, the administration of mefenoxam was associated with a survivability rate of approximately 51%. There was a statistically significant difference in the time to death between cutaneous (245 days (52-530)) and gastrointestinal (90 days (21-203)) groups; dogs infected with cutaneous pythiosis survived significantly longer after being diagnosed with the disease (p = 0.035). The dogs in this
study experienced increased survival rates and time to death, in the absence of side effects due to mefenoxam, compared with previously published literature. The results of this retrospective
study, with some limitations, are promising and should prompt further investigation into the use of mefenoxam in the treatment of both gastrointestinal and cutaneous
pythiosis.